Advertisement

Molecular Biology Reports

, Volume 40, Issue 1, pp 171–176 | Cite as

APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis

Article

Abstract

Published data regarding the association between the apurinic/apyrimidinic endonuclease 1 (APE1) Asp148Glu polymorphism and bladder cancer risk showed inconclusive results. This meta-analysis of literatures was performed to draw a more precise estimation of the relationship. We systematically searched PubMed, Embase, Elsevier and Springer for relevant articles with a time limit of Jan. 2012. The strength of association between APE1 Asp148Glu polymorphism and bladder cancer risk was assessed by odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) using the software STATA(version10.0).A total of 11 case–control studies including 4,292 cases and 4,761 controls based on the search criteria were included for analysis. Overall, for GG versus TT, the pooled OR was 0.952 (95 % CI = 0.778–1.166), for the the G allele carriers (TG + GG) versus homozygote TT, the pooled OR was 0.984 (95 % CI = 0.897–1.078). In the stratified analysis by ethnicity, significantly risks were not found among Asians for GG versus TT (OR = 0.469; 95 % CI = 0.162–1.357) nor (TG + GG) versus TT (OR = 0.921, 95 % CI = 0.742–1.143). Similarly, for non-Asians, significantly risks were also not found for GG versus TT (OR = 0.992; 95 % CI = 0.861–1.144) nor (TG + GG) versus TT (OR = 1.010, 95 % CI = 0.897–1.137). This meta-analysis suggested that the APE1 T1349G (Asp148Glu) polymorphism was not associated with bladder cancer risk among Asians nor non-Asians.

Keywords

Meta-analysis Bladder cancer APE1 Asp148Glu 

References

  1. 1.
    Jemal Ahmedin, Bray Freddie, Melissa M, Ferlay Jacques, Ward Elizabeth (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Bertuccio P, Chatenoud L, Levi F et al (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666–673PubMedCrossRefGoogle Scholar
  3. 3.
    Robson CN, Hochhauser D, Craig R, Rack K, Buckle VJ, Hickson ID (1992) Structure of the human DNA repair gene HAP1 and its localisation to chromosome 14q 11.2-12. Nucleic Acids Res 20:4417–4421PubMedCrossRefGoogle Scholar
  4. 4.
    Evans AR, Limp-Foster M, Kelley MR (2000) Going APE over Ref-1. Mutat Res 461:83–108PubMedCrossRefGoogle Scholar
  5. 5.
    Xanthoudakis S, Miao GG, Curran T (1994) The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci USA 91:23–27PubMedCrossRefGoogle Scholar
  6. 6.
    Robbins J, Dilworth SM, Laskey RA, Dingwall C (1991) Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell 64:615–623PubMedCrossRefGoogle Scholar
  7. 7.
    Tell G, Damante G, Caldwell D, Kelley MR (2005) The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 7:367–384PubMedCrossRefGoogle Scholar
  8. 8.
    Xi T, Jones IM, Mohrenweiser HW (2004) Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics 83:970–979PubMedCrossRefGoogle Scholar
  9. 9.
    Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD (2001) Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22:917–922PubMedCrossRefGoogle Scholar
  10. 10.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  11. 11.
    Ades AE, Lu G, Higgins JP (2005) The interpretation of random-effects meta-analysis in decision models. Med Decis Making 25:646–654PubMedCrossRefGoogle Scholar
  12. 12.
    Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  13. 13.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  14. 14.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634CrossRefGoogle Scholar
  15. 15.
    Mittal RD, Mandal RK, Gangwar R (2011) Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in North Indian population. Mech Ageing Dev. [Epub ahead of print]Google Scholar
  16. 16.
    Wang M, Qin C, Zhu J et al (2010) Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol 29:303–311PubMedCrossRefGoogle Scholar
  17. 17.
    Narter KF, Ergen A, Agaçhan B, Görmüs U, Timirci O, Isbir T (2009) Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res 29:1389–1393PubMedGoogle Scholar
  18. 18.
    Gangwar R, Ahirwar D, Mandhani A, Mittal RD (2009) Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India. Urology 73:675–680PubMedCrossRefGoogle Scholar
  19. 19.
    Andrew AS, Karagas MR, Nelson HH et al (2008) DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered 65:105–118PubMedCrossRefGoogle Scholar
  20. 20.
    Terry PD, Umbach DM, Taylor JA (2006) APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking. Int J Cancer 118:3170–3173PubMedCrossRefGoogle Scholar
  21. 21.
    Broberg K, Björk J, Paulsson K, Höglund M, Albin M (2005) Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Cinogenesis 26:1263–1271CrossRefGoogle Scholar
  22. 22.
    Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X (2007) High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev 16:84–91PubMedCrossRefGoogle Scholar
  23. 23.
    Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, Fontana D (2010) ERCC1 haplotypes modify bladder cancer risk: a case-control study. DNA Repair (Amst) 9:191–200CrossRefGoogle Scholar
  24. 24.
    Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S (2007) Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet 121:233–242PubMedCrossRefGoogle Scholar
  25. 25.
    Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM 3rd (2000) Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res 28:3871–3879PubMedCrossRefGoogle Scholar
  26. 26.
    Yuan L, Gu X, Shao J, Wang M, Wang M, Zhu Q, Zhang Z (2010) Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol 29(10):611–617PubMedCrossRefGoogle Scholar
  27. 27.
    Jiang DK, Ren WH, Yao L, Wang WZ, Peng B, Yu L(2010) Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology. 76(3):765 e1–7Google Scholar
  28. 28.
    Li F, Li C, Jiang Z, Ma N, Gao X(2011) XRCC3 T241 M polymorphism and bladder cancer risk: a meta-analysis. Urology. 77: 511 e1–5Google Scholar
  29. 29.
    Morrison AS, Buring JE, Verhoek WG et al (1984) An international study of smoking and bladder cancer. The Journal of Urology 131:650–654PubMedGoogle Scholar
  30. 30.
    Benhamou S, Sarasin A (2005) ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161:1–14PubMedCrossRefGoogle Scholar
  31. 31.
    Friedberg EC (2003) DNA damage and repair. Nature 421:436–440Google Scholar
  32. 32.
    Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291:1284–1289PubMedCrossRefGoogle Scholar
  33. 33.
    Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP (2006) Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 27:1030–1037PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Department of OncologyChanghai Hospital, Second Military Medical UniversityShanghaiPeople’s Republic of China
  2. 2.Yueyang Second People’s HospitalThe First Affiliated Hospital of University of South ChinaHengyangPeople’s Republic of China
  3. 3.Yueyang Second People’s HospitalYueyangPeople’s Republic of China
  4. 4.Department of Medical OncologyThe First Affiliated Hospital of University of South ChinaHengyangPeople’s Republic of China

Personalised recommendations